INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHY
INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHY
复制标题
DOI：
10.1097/iae.0b013e3182003ccd
复制
发表时间：
2011-07-01
影响因子：
3.3
通讯作者：
Kim, Jung Yeul
中科院分区：
文献类型：
--
作者：
Lee, Yeon Hee;Lee, Eun-Kyoung;Kim, Jung Yeul
目的：评价玻璃体腔注射雷珠单抗（Lucentis）联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变的疗效。回顾性分析了17例17眼有症状的息肉状脉络膜血管病变患者，他们接受了3个月的玻璃体内注射雷珠单抗联合光动力治疗。治疗后随访6个月以上。最佳矫正视力，黄斑中心凹厚度确定的光学相干断层扫描，并在吲哚菁绿色血管造影异常evaluated.Results：平均随访时间为13.8个月。最佳矫正视力的最小分辨角的平均对数在基线时为0.43 +/- 0.36，在治疗后6个月为0.14 +/- 0.24（P = 0.01），在治疗后12个月为0.11 +/- 0.23（P = 0.02）。基线时平均中心凹高度为351 +/- 111 μ m，治疗后6个月为192 +/- 44 μ m（P = 0.02），治疗后12个月为204 +/- 31 μ m（P = 0.01）。在随访期间，患者平均接受3.2次雷珠单抗治疗和1.3次维替泊芬光动力治疗。17只眼中有5只眼进行了再治疗。吲哚菁绿色血管造影显示息肉样病变消退6眼，缩小7眼，无变化4眼。结论：玻璃体内注射雷珠单抗联合光动力治疗可减少血管渗漏，稳定视力，减少渗出性视网膜脱离。联合治疗似乎有助于消退吲哚菁绿色血管造影的息肉样病变，并减少复发。视网膜31：1287-1293，2011
Purpose: To evaluate the efficacy of intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy for patients with polypoidal choroidal vasculopathy.Methods: Retrospective interventional case series. Seventeen eyes of 17 patients with symptomatic polypoidal choroidal vasculopathy who received 3 monthly intravitreal ranibizumab injections with photodynamic therapy were retrospectively reviewed. The follow-up period lasted for more than 6 months after therapy. Best-corrected visual acuity, foveal thickness determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography were evaluated.Results: The mean follow-up period was 13.8 months. The mean logarithm of the minimum angle of resolution best-corrected visual acuity was 0.43 +/- 0.36 at baseline, 0.14 +/- 0.24 at 6 months (P = 0.01), and 0.11 +/- 0.23 at 12 months after treatment (P = 0.02). The mean foveal height was 351 +/- 111 mu m at baseline, 192 +/- 44 mu m at 6 months (P = 0.02), and 204 +/- 31 mu m at 12 months after treatment (P = 0.01). Patients received a mean of 3.2 ranibizumab treatments and 1.3 verteporfin photodynamic therapy treatments over the follow-up period. Re-treatment was performed in 5 of 17 eyes. The polypoidal lesions on indocyanine green angiography were regressed in six eyes, reduced in seven eyes, and unchanged in four eyes.Conclusion: Intravitreal ranibizumab with photodynamic therapy may stabilize visual acuity and reduce exudative retinal detachment because of decreased vascular leaking. The combination treatment appeared to be useful for regressing polypoidal lesions on indocyanine green angiography and in reducing their recurrence. RETINA 31: 1287-1293, 2011